EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 2.0

Enhanced vasoconstriction in sickle cell disease is dependent on ETA receptor activation

John Miller Allan, Brandon M Fox, Malgorzata Kasztan, Gillian C Kelly, Patrick A Molina, McKenzi A King, Jackson Colson, Leigh Wells, Latanya Bowman, Marsha Blackburn, Abdullah Kutlar, Ryan A Harris iD und 2 weitere

Clinical Science · 2024

DOI: 10.1042/cs20240625 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Science, 2024. Verfasst von John Miller Allan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Section of Cardiorenal Physiology & Medicine, Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 352…. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Vasoconstriction, Receptor, Endothelin A. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 2.0). Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, National Heart, Lung, and Blood Institute (NHLBI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sickle cell disease (SCD) carries a significant risk for poor vascular health and vascular dysfunction. High levels of vascular reactive oxygen species (ROS) as well as elevated plasma endothelin-1 (ET-1), a potent vasoconstrictor with actions via the ETA receptor, are both common phenotypes in SCD. Alpha-1 adrenergic receptor activation is a major mediator of stress-induced vasoconstriction. However, the mechanism of the SCD enhanced vasoconstrictive response is unknown. We hypothesized that SCD induces enhanced alpha-1 adrenergic mediated vasoconstriction through the ET-1/ETA receptor pathway in arterial tissues. Utilizing humanized SCD (HbSS) and genetic control (HbAA) mice, alpha-1a, but not alpha-1b or alpha-1d, receptor expression was significantly greater in aortic tissue from HbSS mice compared to HbAA mice. Significantly enhanced vasoconstriction in aortic and carotid arterial segments were observed from HbSS mice compared with HbAA mice. Treatment with ambrisentan, a selective ETA receptor antagonist, and a ROS scavenger normalized the aortic vasoconstrictive response in HbSS mice. In a randomized translational study, patients with SCD were treated with placebo or ambrisentan for 3 months, with the treatment group showing an increase in the percent brachial arterial diameter. Taken together, these data suggest that the ETA receptor pathway interaction with the adrenergic receptor pathway contributes to enhanced aortic vasoconstriction in SCD. Findings indicate the potential of ETA antagonism as a therapeutic avenue for improving vascular health in SCD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellVasoconstrictionReceptor, Endothelin AAnimalsHumansMaleFemaleAdultPhenylpropionatesReactive Oxygen SpeciesReceptors, Adrenergic, alpha-1Endothelin A Receptor AntagonistsEndothelin-1MiceYoung AdultAortaMice, TransgenicPyridazines

Stichwörter der Autor:innen

endothelin-1sickle cell diseasevasoconstriction

Substanzen

Receptor, Endothelin AambrisentanPhenylpropionatesReactive Oxygen SpeciesReceptors, Adrenergic, alpha-1Endothelin A Receptor AntagonistsEndothelin-1Pyridazines

Autor:innen und Institutionen

  • Section of Cardiorenal Physiology & Medicine, Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, U.S.A.
  • Division of Hematology-Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35233, U.S.A.
  • Georgia Prevention Institute, Department of Medicine, Medical College of Georgia at Augusta University, Augusta, GA, U.S.A.
  • Division of Hematology and Oncology, Department of Medicine, Medical College of Georgia at Augusta University, Augusta, GA, U.S.A.

ORCID-Profile: Ryan A Harris, David M Pollock, Jennifer S Pollock

Förderung

  • NHLBI NIH HHS
  • NIDDK NIH HHS
  • National Heart, Lung, and Blood Institute (NHLBI)
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Allan, J. M., Fox, B. M., Kasztan, M., Kelly, G. C., Molina, P. A., King, M. A., Colson, J., Wells, L., Bowman, L., Blackburn, M., Kutlar, A., Harris, R. A., Pollock, D. M., & Pollock, J. S. (2024). Enhanced vasoconstriction in sickle cell disease is dependent on ETA receptor activation. Clinical Science. https://doi.org/10.1042/cs20240625

Vancouver

Allan JM, Fox BM, Kasztan M, Kelly GC, Molina PA, King MA, et al. Enhanced vasoconstriction in sickle cell disease is dependent on ETA receptor activation. Clinical Science. 2024. doi:10.1042/cs20240625

BibTeX
@article{Allan2024,
  author = {Allan, John Miller and Fox, Brandon M and Kasztan, Malgorzata and Kelly, Gillian C and Molina, Patrick A and King, McKenzi A and Colson, Jackson and Wells, Leigh and Bowman, Latanya and Blackburn, Marsha and Kutlar, Abdullah and Harris, Ryan A and Pollock, David M and Pollock, Jennifer S},
  title = {Enhanced vasoconstriction in sickle cell disease is dependent on ETA receptor activation},
  journal = {Clinical Science},
  year = {2024},
  doi = {10.1042/cs20240625}
}
Kostenlos starten →